Samsung Bioepis and Teva Pharmaceutical Industries have reached an agreement to commercialize up to six potential biosimilar candidates from the former, which includes two confirmed investigational candidates, the companies announced.
Samsung Bioepis has announced that both parties have reached a worldwide licensing, development, and commercialization agreement for the potential candidates.
Among these, two confirmed investigational biosimilar candidates include SB41, which references AstraZeneca’s Fasenra, used primarily for severe eosinophilic asthma, and SB44, which references Novartis’ Ilaris, treating various inflammatory conditions such as rare autoinflammatory diseases.
Also Read: Top Leader Urges Advisory Capacity for National Development
According to the agreement, Samsung Bioepis will handle the development, regulatory approval, and production of the biosimilars, whereas Teva will manage commercialization in worldwide markets, such as the U.S., Europe, and Canada. The firms have consented to an option for broadening the collaboration to additional regions.
Samsung Bioepis stated that the agreement strengthens their ongoing partnership, which has previously resulted in the commercialization of Epysqli, a therapy for rare and challenging diseases, in the U.S. The companies have further broadened the partnership to encompass Opuviz, a treatment for ocular conditions, in Canada.
“We are thrilled to expand our successful partnership with Teva with these new biosimilar candidates,” Samsung Bioepis CEO Kim Kyung-ah says.
“This agreement marks another milestone in our shared journey to improve patient access to life-changing medicines.”
Teva's CEO Richard Francis announced that the worldwide multiproduct deal marks an important advancement in expanding Teva's biosimilars operations.
“By combining a strong and growing portfolio and our excellent global commercial capabilities, we are strengthening our leadership position in biosimilars and our ability to bring more treatment options to patients around the world,” Francis says.
Also Read: Mubadala, Kerzner Launch Private Residences on Al Maryah Island
Earlier, Seoul collaborated with Samsung Bioepis to discover and support biotechnology startups focused on advancing drug technologies, enhancing its initiatives to establish a pipeline of future worldwide biotech firms.
The Seoul Metropolitan Government announced Wednesday that it has entered into an agreement with Samsung Bioepis and two chosen startups for the 2026 Seoul Bio Hub-Samsung Bioepis Open Innovation Program.
The signing event occurred at the headquarters of Samsung Bioepis in Songdo, Incheon, with participants from Seoul, Seoul Bio Hub, Samsung Bioepis, an accelerator, and the chosen companies present. The initiative aims to link leading pharmaceutical and biotechnology firms with emerging startups to uncover groundbreaking technologies and hasten the advancement of new drug pipelines.
Seoul announced that the collaboration with Samsung Bioepis represents a growth of its open innovation network, which currently comprises firms like Celltrion and Daewoong Pharmaceutical.
Also Read: Saudi Vision 2030 Programs Achieve 93 Percent Targets
Samsung Bioepis has gained knowledge in the development, global clinical trials, and regulatory approval procedures for antibody-based biosimilars and has recently branched out into new therapeutic fields, such as antibody-drug conjugates and gene therapies. Two startups were chosen based on assessments from both internal and external specialists for their advanced biotechnology platforms.